Xilio Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Xilio Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $1.00K.
- Xilio Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Xilio Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $4.00K, a 300.00% increase year-over-year.
- Xilio Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $5.00K.
- Xilio Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $10.00K, a 100.00% increase from fiscal 2024.
- Xilio Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $5.00K, a 37.50% decline from fiscal 2023.
- Xilio Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $8.00K, a 50.00% decline from fiscal 2022.
- Xilio Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $16.00K, a 94.35% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $10.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $9.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $4.00K 10-Q · filed 2026-08-12 | $13.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $5.00K 10-Q · filed 2026-05-12 | $10.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $5.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $4.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $1.00K 10-Q · filed 2025-08-14 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $8.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $8.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $16.00K 10-K · filed 2024-04-01 | |
| 2022-03-31 | $16.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $283.00K 10-K · filed 2023-03-02 | |
| 2021-09-30 | $14.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $5.00K 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $25.00K 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $159.00K 10-K · filed 2022-03-01 | |
| 2020-09-30 | $6.00K 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |